JP5344764B2 - 黄斑変性におけるオロチン酸カルボキシアミドトリアゾール(cai)の使用方法 - Google Patents
黄斑変性におけるオロチン酸カルボキシアミドトリアゾール(cai)の使用方法 Download PDFInfo
- Publication number
- JP5344764B2 JP5344764B2 JP2009540307A JP2009540307A JP5344764B2 JP 5344764 B2 JP5344764 B2 JP 5344764B2 JP 2009540307 A JP2009540307 A JP 2009540307A JP 2009540307 A JP2009540307 A JP 2009540307A JP 5344764 B2 JP5344764 B2 JP 5344764B2
- Authority
- JP
- Japan
- Prior art keywords
- orotic acid
- angiogenesis
- carboxamidotriazole
- macular degeneration
- cai
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
[実施例1]
オロチン酸カルボキシアミドトリアゾール又は5アミノ1,2,3−トリアゾール(オロチン酸CAI)塩を、米国特許第5,861,406号に記載の手順により調製した。オロチン酸CAIの分子量は581である。
[実施例2]
(オロチン酸カルボキシアミドトリアゾールを用いた血管新生の阻害)
ヒト臍帯静脈内皮細胞(HUVEC:Human umbilical vein endothelial cells)を、3種の異なる濃度のオロチン酸カルボキシアミドトリアゾール又は5アミノ1,2,3−トリアゾール(オロチン酸CAI)を用いて3日間処理をした。異なる処理条件下における各培養物の細胞数を数えた。このアッセイを3回実施し、データは平均±標準偏差として表した。オロチン酸カルボキシアミドトリアゾール又は5アミノ1,2,3−トリアゾール(オロチン酸CAI)は、用量依存的に血管新生を阻害した(図1)。
Claims (2)
- オロチン酸5アミノ1,2,3−カルボキシアミドトリアゾールを含む、黄斑変性の治療における血管新生を抑制するための医薬組成物であって、
前記オロチン酸5アミノ1,2,3−カルボキシアミドトリアゾールが経口投与される、前記医薬組成物。 - 眼内血管新生疾患、糖尿病性網膜症、未熟児網膜症、角膜移植後拒絶反応、血管新生緑内障、水晶体後線維増殖症、ルベオーシス、心筋血管新生、プラーク血管新生、毛細血管拡張症、血友病関節症、血管線維腫、又は創部の肉芽形成からなる群から選択される疾患の治療において、血管新生を抑制するための医薬組成物であって、
オロチン酸5アミノ1,2,3−カルボキシアミドトリアゾールを含み、且つ
前記オロチン酸5アミノ1,2,3−カルボキシアミドトリアゾールが経口投与される、前記医薬組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/634,422 US7750018B2 (en) | 2006-12-06 | 2006-12-06 | Use of carboxiamidotriazole (CAI) orotate in macular degeneration |
US11/634,422 | 2006-12-06 | ||
PCT/US2007/025041 WO2008070169A2 (en) | 2006-12-06 | 2007-12-05 | Use of carboxyamidotriazole (cai) orotate in macular degeneration |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010512318A JP2010512318A (ja) | 2010-04-22 |
JP5344764B2 true JP5344764B2 (ja) | 2013-11-20 |
Family
ID=39492872
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009540307A Active JP5344764B2 (ja) | 2006-12-06 | 2007-12-05 | 黄斑変性におけるオロチン酸カルボキシアミドトリアゾール(cai)の使用方法 |
Country Status (10)
Country | Link |
---|---|
US (2) | US7750018B2 (ja) |
EP (1) | EP2089021B1 (ja) |
JP (1) | JP5344764B2 (ja) |
KR (1) | KR101414922B1 (ja) |
CN (3) | CN104382905A (ja) |
AU (1) | AU2007328027B2 (ja) |
CA (1) | CA2682596C (ja) |
ES (1) | ES2488093T3 (ja) |
IL (1) | IL199158A (ja) |
WO (1) | WO2008070169A2 (ja) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8877785B2 (en) * | 2009-09-04 | 2014-11-04 | Tactical Therapeutics Inc | Methods and compositions for enhancing sensitivity of cytotoxic drugs with timely combinatorial therapy with carboxyamidotriazole orotate |
US9089570B2 (en) * | 2010-09-03 | 2015-07-28 | Tactical Therapeutics Inc | Compositions for treating cancers having acquired resitance to prior chemotherapeutic and targeted drugs using carboxyamidotriazole orotate |
US10378059B2 (en) * | 2013-08-02 | 2019-08-13 | Tactical Therapeutics, Inc. | Methods and molecular pharmacodynamic biomarkers for multiple signaling pathways in response to carboxyamidotriazole orotate |
KR101796684B1 (ko) | 2016-05-19 | 2017-11-10 | 건국대학교 산학협력단 | 케라틴 8 인산화 억제제를 포함하는 황반변성 예방 또는 치료용 약학 조성물 및 황반변성 치료제의 스크리닝 방법 |
CN111253327A (zh) * | 2018-12-03 | 2020-06-09 | 中国医学科学院基础医学研究所 | 羧胺***类化合物或其盐在制备治疗nlrp3炎症小体活化相关疾病的药物中的应用 |
CN111249277A (zh) * | 2018-12-03 | 2020-06-09 | 中国医学科学院基础医学研究所 | 羧胺***类化合物在制备治疗或预防自身炎症性疾病的药物中的应用 |
EP4079309A4 (en) * | 2019-12-16 | 2024-01-10 | Ulsan National Institute Of Science And Tech Unist | COMPOUND FOR INHIBITING ANGIOGENESIS FACTOR AND USE THEREOF |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5304687A (en) * | 1989-12-19 | 1994-04-19 | Farmitalia Carlo Erba S.R.L. | Morpholinyl derivatives of doxorubicin and process for their preparation |
US5196522A (en) * | 1990-11-01 | 1993-03-23 | Board Of Regents, The University Of Texas System | Anthracycline analogues bearing latent alkylating substituents |
US5744492A (en) | 1993-09-17 | 1998-04-28 | United States Of America | Method for inhibiting angiogenesis |
ES2072223B1 (es) * | 1993-11-25 | 1996-03-16 | Lipotec Sa | Liposomas encapsulando doxorubicina. |
US5728707A (en) * | 1995-07-21 | 1998-03-17 | Constantia Gruppe | Treatment and prevention of primary and metastatic neoplasms with salts of aminoimidazole carboxamide |
ATE278399T1 (de) * | 1995-07-21 | 2004-10-15 | Savvipharm Inc | Orotatsalze von 5-amino- oder substituierten amino-1,2,3-triazolen zur behandlung von neoplasmen |
US6210930B1 (en) * | 1997-03-06 | 2001-04-03 | Pharmacia & Upjohn, S.P.A. | Process for preparing doxorubicin |
IL138572A0 (en) * | 1998-03-25 | 2001-10-31 | Biosource Genetics Corp | Benzoate derivatives and pharmaceutical compositions containing the same |
DE69922681T2 (de) * | 1998-10-16 | 2005-05-25 | Mercian Corp. | Kristallisation von doxorubicin-hydrochlorid |
US20050101563A1 (en) * | 2001-08-14 | 2005-05-12 | Pharmacia Corporation | Method and compositions for the treatment and prevention of pain and inflammation |
AU2003296085A1 (en) * | 2002-12-24 | 2004-07-22 | Nitto Boseki Co., Ltd. | Marker proteins for diagnosing liver disease and method of diagnosing liver disease using the same |
CA2581126A1 (en) * | 2004-09-24 | 2006-04-06 | Rfe Pharma Llc | Carboxy-amido-triazoles for the localized treatment of ocular diseases |
US8034823B2 (en) * | 2005-02-22 | 2011-10-11 | Savvipharm Inc | Method of increasing drug oral bioavailability and compositions of less toxic orotate salts |
-
2006
- 2006-12-06 US US11/634,422 patent/US7750018B2/en active Active
-
2007
- 2007-12-05 AU AU2007328027A patent/AU2007328027B2/en active Active
- 2007-12-05 CN CN201410584804.0A patent/CN104382905A/zh active Pending
- 2007-12-05 KR KR1020097011574A patent/KR101414922B1/ko active IP Right Grant
- 2007-12-05 CN CN2013100054685A patent/CN103251601A/zh active Pending
- 2007-12-05 WO PCT/US2007/025041 patent/WO2008070169A2/en active Application Filing
- 2007-12-05 CN CNA2007800454661A patent/CN101578099A/zh active Pending
- 2007-12-05 EP EP07853268.6A patent/EP2089021B1/en active Active
- 2007-12-05 JP JP2009540307A patent/JP5344764B2/ja active Active
- 2007-12-05 ES ES07853268.6T patent/ES2488093T3/es active Active
- 2007-12-05 CA CA2682596A patent/CA2682596C/en active Active
-
2009
- 2009-06-04 IL IL199158A patent/IL199158A/en active IP Right Grant
-
2010
- 2010-05-24 US US12/800,839 patent/US8420658B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN101578099A (zh) | 2009-11-11 |
EP2089021A2 (en) | 2009-08-19 |
US7750018B2 (en) | 2010-07-06 |
AU2007328027B2 (en) | 2012-11-15 |
JP2010512318A (ja) | 2010-04-22 |
US8420658B2 (en) | 2013-04-16 |
CA2682596C (en) | 2014-03-18 |
IL199158A (en) | 2014-07-31 |
US20080139592A1 (en) | 2008-06-12 |
KR101414922B1 (ko) | 2014-07-04 |
US20100298363A1 (en) | 2010-11-25 |
EP2089021B1 (en) | 2014-06-04 |
EP2089021A4 (en) | 2009-12-30 |
AU2007328027A2 (en) | 2010-07-08 |
CN103251601A (zh) | 2013-08-21 |
AU2007328027A1 (en) | 2008-06-12 |
CN104382905A (zh) | 2015-03-04 |
CA2682596A1 (en) | 2008-06-12 |
WO2008070169A3 (en) | 2008-11-06 |
ES2488093T3 (es) | 2014-08-26 |
WO2008070169A2 (en) | 2008-06-12 |
KR20090096442A (ko) | 2009-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5344764B2 (ja) | 黄斑変性におけるオロチン酸カルボキシアミドトリアゾール(cai)の使用方法 | |
JP7475395B2 (ja) | 異常な新生血管形成を伴う眼疾患を処置するためにニンテダニブを使用する組成物および方法 | |
JP2008518922A (ja) | 緑内障性の網膜障害および眼科疾患を処置するためのjunn末端キナーゼのインヒビター | |
JP2002522485A (ja) | 視覚および記憶の疾患のためのピペコリン酸誘導体 | |
KR20180092886A (ko) | 우르소데옥시콜산을 함유하는 시각장애 예방 또는 치료용 조성물 | |
JP2002535370A (ja) | 末梢型ベンゾジアゼピン受容体の機能不全に関連した疾患治療用薬剤の製造用のピリダジノ[4,5−b]インドール−1−アセトアミド誘導体の使用 | |
JP5934229B2 (ja) | 眼血管疾患の処置のための投与計画 | |
CN1203861C (zh) | 含有人参皂甙Rb1的脑血管再生/再造促进剂和继发性神经组织变性抑制剂 | |
JP2005521644A (ja) | 動物における血管新生を制御する方法 | |
CA2697709A1 (en) | Use of compounds derived from cycloheximide for treating or preventing, in particular, ischaemias and cardiopathies | |
WO2021150756A1 (en) | Inhibitors of glutathione s-transferases (gsts) and nad(p)h:quinone oxidoreductase 1 (nqo1), pharmaceutical compositions, and uses in managing cancer | |
KR20120112162A (ko) | 황반변성 예방 또는 치료용 약학 조성물 | |
TW200829261A (en) | Method for controlling angiogenesis in animals | |
AU5397199A (en) | Heterocyclic thioesters or ketones for vision and memory disorders | |
KR20110039842A (ko) | 이미다졸 화합물을 유효성분으로 포함하는 안구의 혈관 신생 관련 질환의 예방 및 치료용 조성물 | |
WO2002032881A1 (fr) | Nouveaux agents therapeutiques ou prophylactiques contre l'angiostenose | |
RU2784443C2 (ru) | Способ подавления роста меланомы В16 у лабораторных животных | |
WO2018027149A1 (en) | Methods of treating alport syndrome | |
JP2024083587A (ja) | 異常な新生血管形成を伴う眼疾患を処置するためにニンテダニブを使用する組成物および方法 | |
Shi et al. | Roles of pyroptosis in myocardial ischemia/reperfusion injury diseases | |
JP3262275B2 (ja) | 照射後の回復を促進するためのリルゾールの応用 | |
TW202227042A (zh) | 雙重鎮痛/消炎組合物、組合及其使用方法 | |
WO2018232238A1 (en) | Therapeutic agent for tuberous sclerosis complex (tsc) | |
US20060252763A1 (en) | Treatment of von hippel lindau disease | |
TH64147A (th) | การใช้ประโยชน์ทางเภสัชกรรมของสารยับยั้ง cox-2 ในความผิดปกติของดวงตาที่สื่อโดยการเจริญเติบโตของเส้นโลหิต |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100603 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20120127 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20120203 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20120127 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120913 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20121213 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20121220 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130213 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130220 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130313 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130424 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130711 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130807 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130812 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5344764 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |